NME2 and metastatic malignant neoplasm: A meta-analysis of 278 patients with colon cancer, 177 with breast cancer, 137 with ovarian cancer and 77 with lung cancer also found a reduced level of NME2 expression in metastatic cancer as compared with non-metastatic cancer [17].